Evaluating the atrial myopathy underlying atrial fibrillation

Identifying the arrhythmogenic and thrombogenic substrate

Jeffrey Goldberger, Rishi Arora, David Green, Philip Greenland, Daniel C. Lee, Donald M. Lloyd-Jones, Michael Markl, Jason Ng, Sanjiv J. Shah

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Atrial disease or myopathy forms the substrate for atrial fibrillation (AF) and underlies the potential for atrial thrombus formation and subsequent stroke. Current diagnostic approaches in patients with AF focus on identifying clinical predictors with the evaluation of left atrial size by echocardiography serving as the sole measure specifically evaluating the atrium. Although the atrial substrate underlying AF is likely developing for years before the onset of AF, there is no current evaluation to identify the preclinical atrial myopathy. Atrial fibrosis is 1 component of the atrial substrate that has garnered recent attention based on newer MRI techniques that have been applied to visualize atrial fibrosis in humans with prognostic implications regarding the success of treatment. Advanced ECG signal processing, echocardiographic techniques, and MRI imaging of fibrosis and flow provide up-to-date approaches to evaluate the atrial myopathy underlying AF. Although thromboembolic risk is currently defined by clinical scores, their predictive value is mediocre. Evaluation of stasis via imaging and biomarkers associated with thrombogenesis may provide enhanced approaches to assess risk for stroke in patients with AF. Better delineation of the atrial myopathy that serves as the substrate for AF and thromboembolic complications might improve treatment outcomes. Furthermore, better delineation of the pathophysiologic mechanisms underlying the development of the atrial substrate for AF, particularly in its earlier stages, could help identify blood and imaging biomarkers that could be useful to assess risk for developing new-onset AF and suggest specific pathways that could be targeted for prevention.

Original languageEnglish (US)
Pages (from-to)278-291
Number of pages14
JournalCirculation
Volume132
Issue number4
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Muscular Diseases
Atrial Fibrillation
Fibrosis
Biomarkers
Stroke
Echocardiography
Electrocardiography
Thrombosis

Keywords

  • arrhythmias, cardiac
  • biological markers
  • cardiovascular imaging agents/techniques
  • clinical medicine
  • diagnostic imaging
  • electrophysiology
  • stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Evaluating the atrial myopathy underlying atrial fibrillation : Identifying the arrhythmogenic and thrombogenic substrate. / Goldberger, Jeffrey; Arora, Rishi; Green, David; Greenland, Philip; Lee, Daniel C.; Lloyd-Jones, Donald M.; Markl, Michael; Ng, Jason; Shah, Sanjiv J.

In: Circulation, Vol. 132, No. 4, 01.01.2015, p. 278-291.

Research output: Contribution to journalArticle

Goldberger, J, Arora, R, Green, D, Greenland, P, Lee, DC, Lloyd-Jones, DM, Markl, M, Ng, J & Shah, SJ 2015, 'Evaluating the atrial myopathy underlying atrial fibrillation: Identifying the arrhythmogenic and thrombogenic substrate', Circulation, vol. 132, no. 4, pp. 278-291. https://doi.org/10.1161/CIRCULATIONAHA.115.016795
Goldberger, Jeffrey ; Arora, Rishi ; Green, David ; Greenland, Philip ; Lee, Daniel C. ; Lloyd-Jones, Donald M. ; Markl, Michael ; Ng, Jason ; Shah, Sanjiv J. / Evaluating the atrial myopathy underlying atrial fibrillation : Identifying the arrhythmogenic and thrombogenic substrate. In: Circulation. 2015 ; Vol. 132, No. 4. pp. 278-291.
@article{11e9ecd1945e435489bddd5b14a4cdb6,
title = "Evaluating the atrial myopathy underlying atrial fibrillation: Identifying the arrhythmogenic and thrombogenic substrate",
abstract = "Atrial disease or myopathy forms the substrate for atrial fibrillation (AF) and underlies the potential for atrial thrombus formation and subsequent stroke. Current diagnostic approaches in patients with AF focus on identifying clinical predictors with the evaluation of left atrial size by echocardiography serving as the sole measure specifically evaluating the atrium. Although the atrial substrate underlying AF is likely developing for years before the onset of AF, there is no current evaluation to identify the preclinical atrial myopathy. Atrial fibrosis is 1 component of the atrial substrate that has garnered recent attention based on newer MRI techniques that have been applied to visualize atrial fibrosis in humans with prognostic implications regarding the success of treatment. Advanced ECG signal processing, echocardiographic techniques, and MRI imaging of fibrosis and flow provide up-to-date approaches to evaluate the atrial myopathy underlying AF. Although thromboembolic risk is currently defined by clinical scores, their predictive value is mediocre. Evaluation of stasis via imaging and biomarkers associated with thrombogenesis may provide enhanced approaches to assess risk for stroke in patients with AF. Better delineation of the atrial myopathy that serves as the substrate for AF and thromboembolic complications might improve treatment outcomes. Furthermore, better delineation of the pathophysiologic mechanisms underlying the development of the atrial substrate for AF, particularly in its earlier stages, could help identify blood and imaging biomarkers that could be useful to assess risk for developing new-onset AF and suggest specific pathways that could be targeted for prevention.",
keywords = "arrhythmias, cardiac, biological markers, cardiovascular imaging agents/techniques, clinical medicine, diagnostic imaging, electrophysiology, stroke",
author = "Jeffrey Goldberger and Rishi Arora and David Green and Philip Greenland and Lee, {Daniel C.} and Lloyd-Jones, {Donald M.} and Michael Markl and Jason Ng and Shah, {Sanjiv J.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1161/CIRCULATIONAHA.115.016795",
language = "English (US)",
volume = "132",
pages = "278--291",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Evaluating the atrial myopathy underlying atrial fibrillation

T2 - Identifying the arrhythmogenic and thrombogenic substrate

AU - Goldberger, Jeffrey

AU - Arora, Rishi

AU - Green, David

AU - Greenland, Philip

AU - Lee, Daniel C.

AU - Lloyd-Jones, Donald M.

AU - Markl, Michael

AU - Ng, Jason

AU - Shah, Sanjiv J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Atrial disease or myopathy forms the substrate for atrial fibrillation (AF) and underlies the potential for atrial thrombus formation and subsequent stroke. Current diagnostic approaches in patients with AF focus on identifying clinical predictors with the evaluation of left atrial size by echocardiography serving as the sole measure specifically evaluating the atrium. Although the atrial substrate underlying AF is likely developing for years before the onset of AF, there is no current evaluation to identify the preclinical atrial myopathy. Atrial fibrosis is 1 component of the atrial substrate that has garnered recent attention based on newer MRI techniques that have been applied to visualize atrial fibrosis in humans with prognostic implications regarding the success of treatment. Advanced ECG signal processing, echocardiographic techniques, and MRI imaging of fibrosis and flow provide up-to-date approaches to evaluate the atrial myopathy underlying AF. Although thromboembolic risk is currently defined by clinical scores, their predictive value is mediocre. Evaluation of stasis via imaging and biomarkers associated with thrombogenesis may provide enhanced approaches to assess risk for stroke in patients with AF. Better delineation of the atrial myopathy that serves as the substrate for AF and thromboembolic complications might improve treatment outcomes. Furthermore, better delineation of the pathophysiologic mechanisms underlying the development of the atrial substrate for AF, particularly in its earlier stages, could help identify blood and imaging biomarkers that could be useful to assess risk for developing new-onset AF and suggest specific pathways that could be targeted for prevention.

AB - Atrial disease or myopathy forms the substrate for atrial fibrillation (AF) and underlies the potential for atrial thrombus formation and subsequent stroke. Current diagnostic approaches in patients with AF focus on identifying clinical predictors with the evaluation of left atrial size by echocardiography serving as the sole measure specifically evaluating the atrium. Although the atrial substrate underlying AF is likely developing for years before the onset of AF, there is no current evaluation to identify the preclinical atrial myopathy. Atrial fibrosis is 1 component of the atrial substrate that has garnered recent attention based on newer MRI techniques that have been applied to visualize atrial fibrosis in humans with prognostic implications regarding the success of treatment. Advanced ECG signal processing, echocardiographic techniques, and MRI imaging of fibrosis and flow provide up-to-date approaches to evaluate the atrial myopathy underlying AF. Although thromboembolic risk is currently defined by clinical scores, their predictive value is mediocre. Evaluation of stasis via imaging and biomarkers associated with thrombogenesis may provide enhanced approaches to assess risk for stroke in patients with AF. Better delineation of the atrial myopathy that serves as the substrate for AF and thromboembolic complications might improve treatment outcomes. Furthermore, better delineation of the pathophysiologic mechanisms underlying the development of the atrial substrate for AF, particularly in its earlier stages, could help identify blood and imaging biomarkers that could be useful to assess risk for developing new-onset AF and suggest specific pathways that could be targeted for prevention.

KW - arrhythmias, cardiac

KW - biological markers

KW - cardiovascular imaging agents/techniques

KW - clinical medicine

KW - diagnostic imaging

KW - electrophysiology

KW - stroke

UR - http://www.scopus.com/inward/record.url?scp=84938595511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938595511&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.115.016795

DO - 10.1161/CIRCULATIONAHA.115.016795

M3 - Article

VL - 132

SP - 278

EP - 291

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 4

ER -